Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
Watanabe R, Ebina K, Gon T, Okano T, Murata K, Murakami K, Maeda Y, Jinno S, Shirasugi I, Son Y, Amuro H, Katayama M, Hara R, Hata K, Yoshikawa A, Yamamoto W, Tachibana S, Hayashi S, Etani Y, Katsushima M, Fukumoto K, Yamada S, Hashimoto M. Watanabe R, et al. Among authors: ebina k. Rheumatology (Oxford). 2024 May 9:keae265. doi: 10.1093/rheumatology/keae265. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38724245
The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis.
Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S, Tanaka I, Kitajima Y, Kubota T, Ebina K, Takashi Y, Inoue R, Yamauchi M, Okubo N, Ueno M, Ohata Y, Ito N, Ozono K, Nakayama H, Terauchi M, Tanaka S, Fukumoto S. Tanaka Y, et al. Among authors: ebina k. J Bone Miner Metab. 2024 Mar;42(2):143-154. doi: 10.1007/s00774-024-01502-w. Epub 2024 Mar 28. J Bone Miner Metab. 2024. PMID: 38538869 Free PMC article.
Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study.
Shirasugi I, Onishi A, Nishimura K, Yamamoto W, Murakami K, Onizawa H, Maeda Y, Ebina K, Son Y, Amuro H, Katayama M, Hara R, Nagai K, Hiramatsu Y, Hashimoto M, Okano T, Maeda T, Hayashi S, Sendo S, Jinno S, Yamamoto Y, Yamada H, Ueda Y, Saegusa J. Shirasugi I, et al. Among authors: ebina k. Int J Rheum Dis. 2024 Mar;27(3):e15097. doi: 10.1111/1756-185X.15097. Int J Rheum Dis. 2024. PMID: 38439176
Iguratimod suppresses sclerostin and receptor activator of NF-κB ligand production via the extracellular signal-regulated kinase/early growth response protein 1/tumor necrosis factor alpha pathway in osteocytes and ameliorates disuse osteoporosis in mice.
Miura T, Etani Y, Noguchi T, Hirao M, Takami K, Goshima A, Kurihara T, Fukuda Y, Ochiai N, Kanamoto T, Nakata K, Okada S, Ebina K. Miura T, et al. Among authors: ebina k. Bone. 2024 Apr;181:117026. doi: 10.1016/j.bone.2024.117026. Epub 2024 Feb 5. Bone. 2024. PMID: 38325651
Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Jinno S, Onishi A, Hattori S, Dubreuil M, Ueda Y, Nishimura K, Okano T, Yamada H, Yamamoto W, Murata K, Onizawa H, Ebina K, Maeda Y, Son Y, Amuro H, Hara R, Hata K, Shiba H, Katayama M, Watanabe R, Hashimoto M, Saegusa J. Jinno S, et al. Among authors: ebina k. Rheumatology (Oxford). 2024 Feb 6:keae081. doi: 10.1093/rheumatology/keae081. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38317442
An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
Ebina K, Nagayama Y, Kashii M, Tsuboi H, Okamura G, Miyama A, Etani Y, Noguchi T, Hirao M, Miura T, Fukuda Y, Kurihara T, Nakata K, Okada S. Ebina K, et al. Osteoporos Int. 2024 May;35(5):841-849. doi: 10.1007/s00198-024-07019-2. Epub 2024 Jan 31. Osteoporos Int. 2024. PMID: 38296866 Free PMC article.
425 results